Publication of Crossject voting rights and shares

Crossject, a company specializing in emergency medications, has announced the total number of voting rights and shares in its capital as of May 31, 2025. In total, the company has 46,230,346 shares. The number of theoretical voting rights is 56,135,780, while the number of exercisable voting rights is 56,025,335. These figures result from the subtraction of shares deprived of voting rights, which amount to 110,445, including 66,689 shares held by the company and 43,756 registered under the liquidity contract.

This information is published in accordance with AMF regulations and the French Commercial Code. It provides an up-to-date overview of the capital structure of Crossject, whose business focuses on the development and commercialization of innovative pharmaceutical solutions for emergency situations.